 BERKELEY, Calif., Aug. 25, 2021 GLOBE NEWSWIRE -- Caribou Biosciences, Inc. Nasdaq: CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Nancy Whiting, Pharm.D., to its board of directors. Dr. Whiting brings over 17 years of biotechnology industry expertise in drug and portfolio development, as well as significant strategic leadership experience. 